…of study participants and sites: This phase II study aims to recruit participants from approximately 70 sites in Argentina, Australia, Austria, Canada, Denmark, France, Germany, Italy, New Zealand, Poland, Spain,… […]
…have a crucial role in working with local health systems and regulators, industry partners, patient groups to prepare for new treatments. I am honoured to be asked to stand for… […]
…end she was passionately providing care and counseling for HD families. She was hopeful for the new HD therapies on the horizon. She will be missed in the HD community,… […]
…VIDEO Wild-type Huntingtin: Evolution, Structure, Function Elena Cattaneo Remembering Lesley Jones Anne Rosser and Sarah Tabrizi PLENARY SESSION I: New Genetics of HD; Chaired by Hoa Huu Phuc Nguyen and… […]
…Formulating key scientific and EHDN strategic questions Identifying potential collaborators or funding opportunities for research Creating and supporting Task Forces to address specific scientific questions proposed by the Think Tank… […]
…GENERATION HD1 – This Phase 3 trial was stopped in March 2021 following a benefit–risk assessment by an independent data monitoring committee. A letter published 07/12/2023 in the New… […]
…The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists…. […]
…and/or outcomes for clinical trials for approval of new treatments for HD. Projects Previous projects Within this newly founded WG no collaborative projects were established or started yet. However, all… […]
…Diseases Bonn, Germany email: patrick.weydt@uni-bonn.de Jamie Levey Chief Operating Officer New York, USA email: jamie@euro-hd.net Franziska Steck Project Manager Ulm, Germany email: franziska.steck@uniklinik-ulm.de Tim McLean Clinical Operation Manager Edinburgh, U.K…. […]
